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Previews
stimulation by stress-related pathways, the initial trans-Unraveling the NALP-3/IL-1
lation product is an inactive precursor. In vitro, stimu-Inflammasome: A Big Lesson lated human blood monocytes release less than 10%
of the IL-1 intracellular pool into the extracellular com-from a Small Mutation
partment. Biologically active IL-1 is released from the
cell following cleavage by an intracellular cysteine prote-
ase formerly called IL-1 converting enzyme, which is
Cytokine-mediated inflammation is a target for novel now termed caspase-1. Caspase-1 is the first member
therapies as well as for fundamental research. A single of a large family of intracellular proteases regulating
amino acid mutation in the NALP-3 gene controlling programmed cell death, but there is little evidence that
the activation of caspase-1 results in increased pro- caspase-1 participates in cell death. Other levels of con-
cessing of the inactive IL-1 precursor and release of trol over the release of IL-1 have been described, such
the active cytokine. Blocking IL-1 receptors arrests as the P2X7 receptor (Solle et al., 2001) and specialized
endolysosomes (Andrei et al., 1999). The Figure illus-inflammation in humans with the mutation.
trates the events in production, cleavage, and release
of active IL-1 from endotoxin-stimulated human bloodThe most convincing experimental result in cytokine
monocytes.biology is the near complete reversal of the pathological
In the report by the group of Tschopp (Agostini et al.,consequences of a complex disease upon specific
2004 [this issue of Immunity]), attention was focusedblockade of a single cytokine. Most autoimmune/inflam-
on the activation of caspase-1 and specifically on thematory diseases are associated with a large portfolio of
release of IL-1. For the past 5 years, studies on thecytokines, and not uncommonly, disease severity corre-
activation of the caspase family have revealed the par-lates with elevated cellular production or circulating lev-
ticipation of several proteins, which, after oligomeriza-els. But associations do not prove causation. Humans
tion, form a scaffold of protein-protein interactions. Onewith Muckle-Wells syndrome, a rare autosomal domi-
of these oligomerized scaffolds has been termed thenant disease, suffer from recurrent fevers, neutrophilia,
inflammasome because it is responsible for activationelevated acute phase proteins, painful arthritis, skin
of caspase-1 (Tschopp et al., 2003). In stimulated cellsrashes, and congenital deafness. The genetic defect in
replete with the IL-1 precursor, the rate-limiting stepthese patients is found in a gene encoding NALP-3,
for cleavage is the activation of caspase-1. Caspase-1which is a member of a family of proteins involved in
is constitutively expressed in phagocytic cells as aninflammation (Tschopp et al., 2003). Mutations in NALP-3
inactive proenzyme, requiring two proteolytic steps tohave also been described in subjects with similar syn-
form the active heterodimer. In fact, like other membersdromes (Hawkins et al., 2004). Although there are some
of the caspase family, autocatalysis of pro-caspase-1
23 NALP-3 mutations described, each results in the
by caspase-1 itself accounts for the activation. How-
change of a single amino acid. Upon treatment with the
ever, the initial trigger for activation apparently is related
interleukin-1 (IL-1) receptor antagonist (anakinra), there to the assembly of the protein scaffold now called the
is a rapid (within days) and near complete reduction in inflammasome, which contains NALP-1, an adaptor pro-
each of the inflammatory manifestations of the syn- tein called ASC, and pro-caspase-1. The interaction of
drome (Hawkins et al., 2004). The rapid response to the caspase-recruiting domain (CARD) of pro-caspase-1
IL-1 receptor blockade demonstrates that the local and is mediated by the CARD of ASC and the CARD present
systemic manifestations of Muckle-Wells syndrome are at the C terminus of NALP-1. Meanwhile, various NALP1-
due to IL-1, since the IL-1 receptor antagonist only related proteins, called NALP-2 through 14, were identi-
blocks IL-1 activity. Importantly, the clinical and bio- fied and proposed to build inflammosome-like platforms
chemical markers of the syndrome are common to most (Tschopp et al., 2003). In patients with the Muckle-Wells
infectious and autoimmune diseases and implicate IL-1 syndrome, the mutations in NALP-3 presented a di-
as a key mediator of systemic and local inflammation. lemma for activating caspase-1 in that NALP-3 belongs
IL-1 is a highly potent proinflammatory cytokine. The to a subfamily of NALP proteins, which are missing the
intravenous injection of only a few hundred nanograms carboxy-terminal CARD-containing region (see NALP-3
of IL-1 into humans evokes fever, leukocytosis, throm- in the Figure).
bocytosis, hypotension, the release of ACTH, the pro- The observations by Agostini et al. (2004) help unravel
duction of cytokines such as IL-6, which in turn, induces the molecular basis for activating caspase-1 by NALP3
the synthesis of hepatic acute phase proteins serum and shed considerable light on what takes place in cells
amyloid A (SAA) and C-reactive protein (reviewed in from patients with the mutations. A single mutation in
Dinarello, 1996). In patients with Muckle-Wells syn- NALP3 results in a high state of activation of caspase-1
drome, dangerously high levels of SAA associated with in endotoxin-stimulated human monocytes with greater
fatal renal amyloidosis fall dramatically upon initiation release of IL-1 compared to cells from patients without
of IL-1 receptor antagonist therapy (Hawkins et al., 2003, a mutation. As shown in the Figure, the caspase-1 acti-
2004). It is not surprising that during infection, trauma, vation scaffold for NALP3 circumvents the protein-pro-
or inflammation, the production of active IL-1 is tightly tein interaction of the NALP-1 CARD by the participation
of other CARD proteins called Cardinal and ASC. Like incontrolled. In health, IL-1 is not expressed, but upon
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Figure 1. Role of the IL-1 Inflammasome in
the Activation of Caspase-1 and Release of
Active IL-1
Human monocytes stimulated with endotoxin
accumulate inactive IL-1 precursors in the
cytosol. Inactive pro-caspase-1 is constitu-
tively present in these cells. The IL-1 inflam-
masome, composed of a scaffold of interacting
proteins, activates pro-caspase-1. The cas-
pase-recruitment domain (CARD) on the pro-
caspase-1 interacts with CARD of an adaptor
protein called ASC. The pyrin (PYD) domain
of ASC binds to the PYD domain of NALP-3.
NALP-3 is comprised of the NACHT domain,
in which each of the mutations of Muckle-
Wells syndrome are found; the NALP-associ-
ated domain (NAD); and ends with leucine-
rich repeats (LRR). The CARD of caspase-1
also interacts with CARD of a protein called
Cardinal, which binds to NACHT in NALP-3
with its N-terminal domain (FIIND). The oligo-
merization of these proteins results in activa-
tion of caspase-1, which then associates with
the IL-1 precursor at the inner leaflet of the
cell’s membrane. There cleavage takes place
and active IL-1 is secreted from the cell. It is likely that more than one mechanism is involved in the secretion event. In monocytes from
subjects with Muckle-Wells syndrome bearing the mutation in NACHT (R260W), greater amounts of active IL-1 are found in the extracellular
compartment compared to cells without the mutation. High levels of secreted active IL-1 likely leads to local and systemic inflammation
associated with the mutation since the IL-1 receptor antagonist reverses the syndrome within days.
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that CD38 links innate and adaptive immunity by trig-All Roads Lead to Rome:
gering chemokine-mediated dendritic cell chemotaxis.Triggering Dendritic Cell Migration
Primary humoral responses are initiated by the ligation
of the B cell receptor (BCR) by antigen and concomitant
T cell help, which provides distinct signals for B cell
activation and differentiation. Previous work has sug-Migration of dendritic cells to secondary lymphatic
organs is a key event in acquired immunity. The role gested that the cell surface antigen CD38 acts as a
coreceptor for the BCR as well as the TCR/CD3 complexof the multifunctional ectoenzyme CD38 in humoral
immune responses has now been revisited, suggesting and modulates both B cell and T cell activation and
